Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruitingRare disease

Study on the Safety of Lutetium (177Lu) Oxodotreotide, L-Lysine Hydrochloride, and L-Arginine Hydrochloride in Adolescents with Neuroendocrine Tumors and PPGLs

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying certain types of tumors, specifically gastroenteropancreatic neuroendocrine tumors (GEP-NETs), pheochromocytoma, and paragangliomas. These are rare types of tumors that can occur in the digestive system and other parts of the body. The study is testing a treatment called Lutathera, which is a solution given through an infusion into the veins. Lutathera contains a substance called lutetium (177Lu) oxodotreotide, which is designed to target and treat these tumors.

The purpose of the study is to evaluate how safe Lutathera is for use in adolescents and to understand how the body absorbs the radiation from this treatment. Another medication used in the study is called LysaKare, which contains L-lysine hydrochloride and L-arginine hydrochloride. These are amino acids that help protect the kidneys during the treatment. The study will involve monitoring the participants over a period of time to see how their bodies respond to the treatment and to check for any side effects.

Participants in the study will receive the treatment over a period of up to 36 months. During this time, doctors will closely monitor the participants' health and the effects of the treatment. The study aims to gather information on the safety and effectiveness of Lutathera in treating these specific types of tumors in adolescents. This information will help in understanding how well the treatment works and its potential side effects.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial assessment

    Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes verifying the presence of specific tumors and the expression of somatostatin receptors through imaging tests.

    The assessment ensures that the patient is between 12 and 18 years old and meets the required health performance status.

  2. Step 2

    Treatment administration

    The treatment involves the administration of Lutathera, a solution for infusion, given intravenously. This medication is used to target specific tumors.

    Alongside Lutathera, LysaKare is also administered intravenously to protect the kidneys during treatment.

  3. Step 3

    Monitoring and evaluation

    After the administration of Lutathera, the patient is monitored for any immediate adverse effects or laboratory abnormalities.

    The primary focus is on evaluating the radiation doses absorbed by organs such as the kidneys and bone marrow.

  4. Step 4

    Short-term follow-up

    For six months following the last dose of Lutathera, the patient undergoes regular check-ups to monitor for any adverse events or laboratory toxicities.

    These follow-ups help in assessing the short-term safety and tolerability of the treatment.

  5. Step 5

    Long-term follow-up

    The long-term follow-up extends up to five years after the final dose of Lutathera. During this period, the patient is periodically evaluated for any long-term adverse effects or laboratory abnormalities.

    This stage aims to ensure the continued safety and effectiveness of the treatment over an extended period.

Who can join the trial?

5 criteria

  • The patient must have a type of tumor called **GEP-NET** or **PPGL** that has spread or cannot be removed by surgery. These tumors must be confirmed by a test called a **histological test**, which examines tissue under a microscope.
  • The patient must be between 12 and 17 years old at the time they join the study.
  • The patient must have **somatostatin receptors** on their tumors, confirmed by a special imaging test done within 3 months before joining the study. The test should show that the tumor absorbs a substance as much as or more than the normal liver does.
  • The patient must have a certain level of physical ability, measured by a **Karnofsky score** or **Lansky Play-Performance Scale score** of 50 or higher. These scores help determine how well the patient can perform daily activities.
  • The patient's parent or guardian must be able to understand and agree to sign a consent form, which is a document that explains the study and what it involves. The adolescent will also need to agree to participate by signing a form, along with their parent or guardian, according to local rules.

Who cannot join the trial?

10 criteria

  • Patients who do not have **somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors**. These are specific types of tumors that affect the stomach, intestines, and pancreas and have certain receptors on their surface.
  • Patients who do not have **pheochromocytoma** or **paragangliomas**. These are rare types of tumors that usually develop in the adrenal glands or along nerve pathways in the body.
  • Patients who are not within the specified age range for the study.
  • Patients who are not able to safely receive the study treatment due to other health conditions.
  • Patients who are pregnant or breastfeeding.
  • Patients who are unable to follow the study procedures or attend required visits.
  • Patients who have participated in another clinical trial recently.
  • Patients who have certain medical conditions that might interfere with the study treatment.
  • Patients who are taking medications that could affect the study results.
  • Patients who have allergies to the study medication or its ingredients.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Lutathera is a medication used in this clinical trial to treat certain types of tumors that have specific receptors called somatostatin receptors. These tumors include gastroenteropancreatic neuroendocrine tumors (GEP-NETs), pheochromocytomas, and paragangliomas. The trial aims to assess how safe Lutathera is for adolescent patients and how the body absorbs the radiation from this treatment.

What is already known about the treatment

Lutathera – Lutathera is administered intravenously and is used in the treatment of certain types of tumors, specifically those that are positive for somatostatin receptors, such as gastroenteropancreatic neuroendocrine tumors, pheochromocytoma, and paragangliomas. It is currently being studied in clinical trials to assess its safety and effectiveness in adolescent patients. The medication works by delivering targeted radiation to cancer cells, which helps to reduce tumor size and slow disease progression. Lutathera is classified as a radiopharmaceutical, which means it combines a radioactive component with a drug to target specific cells in the body.

Investigated diseases

  • Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

    These are a group of rare tumors that arise from neuroendocrine cells in the gastrointestinal tract and pancreas. They can produce hormones that cause various symptoms, depending on the location and type of tumor. GEP-NETs can grow slowly or rapidly, and their progression varies widely among individuals. They may remain localized or spread to other parts of the body over time.

  • Pheochromocytoma

    This is a rare tumor that develops in the adrenal glands, which are located above the kidneys. It often causes the glands to produce excess hormones, leading to symptoms like high blood pressure, headaches, and sweating. The tumor can grow slowly and may remain confined to the adrenal glands or spread to other areas.

  • Paragangliomas

    These are rare tumors that originate from nerve tissue outside the adrenal glands. They can occur in various parts of the body and may produce hormones that lead to symptoms similar to pheochromocytomas. Paragangliomas can grow at different rates and may remain localized or spread to other regions.

Trial detailsLast updated 7 Oct 2026
Age0-17PhasePhase IITrial ID2023-507444-37-00Protocol codeCAAA601A32201Estimated enrolment11 patientsSponsorAdvanced Accelerator Applications

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.